We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
14
Research Clients
130
Reports published
10k+
Readers in database
The offer period for @NexstimOyj's warrant offering (fully underwritten) has opened and the company aims to place additional shares at the same time. Overall, c €2.8m net should be raised, extending its cash runway into Q320. Read our note at
https://t.co/DKgtKvYekJ
.@NexstimOyj continues to gain momentum with the launch of its NBT system for the treatment of depression (#MDD). Read our note on Nexstim following its Q3 trading update at https://t.co/DKgtKvYekJ
Selectivity of @HChiMed TKIs supports exploring combination approaches to improve treatment of solid tumours, & positively the global Innovent Biologics PD-1 collaboration has been expanded to include #surufatinib as well as #fruquintinib $HCM
https://t.co/MbwSVLk645
A potential tie up between @NexstimOyj & a leading California-based academic institution could open a new inpatient TMS market in severe #depression with limited competition. Read our preliminary assessment of the opportunity for $NXTMH/ $NXTMS: https://t.co/DKgtKvYekJ
$MXCT.L secures sixth non-exclusive commercial licence. The deal with @editasmed is evidence of the increasing relevance of @MaxCyte_info‘s non-viral approach & reinforces its position as a key enabler for gene-edited therapies. Read our Update note at: https://t.co/I9vIBMeb3C
Megakaryocyte analysis for assessing cancer prognosis could open up a new opportunity for ANGLE plc and its @Parsortix device, following the granting of a European patent to Queen Mary University of London (@QMUL), as ANGLE plc has an option on the patent https://t.co/INXgkxBmti
Please sign up here to be added to our distribution database
